^
Association details:
Biomarker:TP53 mutation
Cancer:Leiomyosarcoma
Drug:dacarbazine (DNA synthesis inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma

Published date:
05/15/2020
Excerpt:
ATRX andTP53 mutations were not linked with clinical benefit/response to DTIC.